江苏鼎泰药物研究(集团)股份有限公司

I.CENTURY HLDG

RIVERINE CHINA

KOS TALENT GP

CHINA CBS INTL

NATURE ENERGY T

DIGIT HOLLYWOOD

REDCO HEALTHY

ZXZN QI-HOUSE

ASIA PIONEER

HUISHENG INTL

002675

688488

<p>Jiangsu Aidea Pharmaceutical plans to pursue an IPO in Hong Kong to facilitate its expansion into the US and European markets. The company, currently listed on the Shanghai Stock Exchange, views Hong Kong as a strategic entry point due to its flexible fundraising environment. With expectations for the Aids treatment sector to exceed 10 billion yuan by 2027, Jiangsu Aidea aims to develop competitive products and has initiated discussions with Hong Kong's drug regulator. The company recently announced a financing plan of 1.2 billion yuan, primarily for US clinical projects.</p>

SCMP

Dongcheng Biochem

Aidea Pharma

China’s Jiangsu Aidea eyes Hong Kong IPO as gateway to US, European Aids markets

江苏鼎泰药物研究(集团)股份有限公司(N25311.HK)

China’s Jiangsu Aidea eyes Hong Kong IPO as gateway to US, European Aids markets